Peripheral arterial disease of the lower extremities.

Health Effects of the Programmed Physical Activities on Lipid Profile in Peripheral Arterial Disease of the Lower Extremities. Med Arch (2015) 0.75

Improvement of hepatic bioavailability as a new step for the future of statin. Arch Med Sci (2015) 0.75

Impact of betablockers on general and local outcome in patients hospitalized for lower extremity peripheral artery disease: The COPART Registry. Medicine (Baltimore) (2017) 0.75

Epicardial fat thickness and oxidative stress parameters in patients with subclinical hypothyroidism. Arch Med Sci (2017) 0.75

Combined autologous bone marrow mononuclear cell and gene therapy as the last resort for patients with critical limb ischemia. Arch Med Sci (2014) 0.75

Comparison of results of endovascular stenting and bypass grafting for TransAtlantic Inter-Society (TASC II) type B, C and D iliac occlusive disease. Arch Med Sci (2016) 0.75

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (2002) 20.22

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 16.32

Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA (2001) 13.65

ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation (2006) 13.21

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA (1995) 11.45

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (2000) 10.66

A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med (1997) 9.73

Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med (1992) 8.94

Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet (2005) 7.25

Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med (1991) 6.03

Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg (2000) 5.50

Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA (2010) 5.10

Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation (1993) 4.75

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J (2011) 4.47

Medical treatment of peripheral arterial disease and claudication. N Engl J Med (2001) 3.92

Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA (2001) 3.90

Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA (1995) 3.57

The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest (1975) 3.40

Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol (1998) 3.37

The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med (2002) 3.32

Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation (2009) 3.28

Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation (1996) 3.23

The prevalence of peripheral arterial disease in a defined population. Circulation (1985) 2.88

ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol (2011) 2.83

Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med (2006) 2.73

Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol (2008) 2.38

Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J (2002) 2.38

Arteriosclerosis obliterans: review of 520 cases with special reference to pathogenic and prognostic factors. Circulation (1960) 2.35

Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet (2000) 2.19

Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation (1990) 2.15

The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol (2010) 2.15

Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg (2007) 2.08

Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. N Engl J Med (1988) 2.06

Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA (1993) 2.06

Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med (1998) 1.98

Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation (2003) 1.93

Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation (2003) 1.90

Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J (2004) 1.90

Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J (1982) 1.82

Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J (2009) 1.80

Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med (1991) 1.76

Chelation therapy for peripheral arterial occlusive disease: a systematic review. Circulation (1997) 1.70

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation (1998) 1.64

Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. J Am Coll Cardiol (2011) 1.58

Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol (2003) 1.54

Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60-year-old men and women. J Chronic Dis (1981) 1.52

The effect of smoking on the late patency of arterial reconstructions in the legs. Br J Surg (1978) 1.51

Combined role of reduced estimated glomerular filtration rate and microalbuminuria on the prevalence of peripheral arterial disease. Am J Cardiol (2009) 1.51

Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation (2003) 1.51

A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life. J Am Coll Cardiol (2008) 1.50

Greater sedentary hours and slower walking speed outside the home predict faster declines in functioning and adverse calf muscle changes in peripheral arterial disease. J Am Coll Cardiol (2011) 1.49

Mortality over four years in SHEP participants with a low ankle-arm index. J Am Geriatr Soc (1997) 1.45

Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation (1994) 1.41

Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation (1989) 1.40

Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol (1994) 1.35

Physical activity during daily life and functional decline in peripheral arterial disease. Circulation (2008) 1.34

Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol (1998) 1.32

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation (2001) 1.32

The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation (1987) 1.31

Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation (2003) 1.28

Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. Circulation (2011) 1.27

Duplex scanning for diagnosis of aortoiliac and femoropopliteal disease: a prospective study. Circulation (1987) 1.24

Sex differences in peripheral arterial disease: leg symptoms and physical functioning. J Am Geriatr Soc (2003) 1.24

Restenosis after coronary placement of various stent types. Am J Cardiol (2001) 1.24

Intermittent claudication: prevalence and risk factors. Br Med J (1978) 1.23

Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand (1982) 1.21

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg (1998) 1.20

Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med (2003) 1.17

Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol (2002) 1.17

AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol (2001) 1.17

Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb (1992) 1.16

Osteoporosis, osteopenia, and atherosclerotic vascular disease. Arch Med Sci (2011) 1.16

A propensity-matched study of the association of peripheral arterial disease with cardiovascular outcomes in community-dwelling older adults. Am J Cardiol (2008) 1.15

A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med (2000) 1.12

The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol (2006) 1.09

Prevalence of left main coronary artery disease, of three- or four-vessel coronary artery disease, and of obstructive coronary artery disease in patients with and without peripheral arterial disease undergoing coronary angiography for suspected coronary artery disease. Am J Cardiol (2003) 1.09

Placement of balloon-expandable intraluminal stents in iliac arteries: first 171 procedures. Radiology (1990) 1.07

Prevalence of transthoracic echocardiographic abnormalities in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Arch Med Sci (2010) 1.07

The measured effect of stopping smoking on intermittent claudication. Br J Surg (1982) 1.04

Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc (1999) 1.04

Association of ankle-brachial index with severity of angiographic coronary artery disease in patients with peripheral arterial disease and coronary artery disease. Cardiology (2005) 1.03

Improved functional outcomes following exercise rehabilitation in patients with intermittent claudication. J Gerontol A Biol Sci Med Sci (2000) 1.03

Smoking, smoking cessation, [corrected] and risk for symptomatic peripheral artery disease in women: a cohort study. Ann Intern Med (2011) 1.02

Treating tobacco addiction--nicotine or no nicotine? N Engl J Med (1997) 1.02

Peripheral arterial disease and progression of coronary atherosclerosis. J Am Coll Cardiol (2011) 1.00

Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol (2003) 0.98

Prediction of late cardiac events by dipyridamole thallium imaging in patients undergoing elective vascular surgery. Am J Cardiol (1992) 0.98

Thoracic aortic atheroma severity predicts high-risk coronary anatomy in patients undergoing transesophageal echocardiography. Arch Med Sci (2011) 0.96

Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. J Am Coll Cardiol (1994) 0.95

Women with peripheral arterial disease experience faster functional decline than men with peripheral arterial disease. J Am Coll Cardiol (2011) 0.93

Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol (2002) 0.93

State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension (1999) 0.91

Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility. J Gerontol A Biol Sci Med Sci (2002) 0.91

Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol (2002) 0.91

Prevalence of symptomatic peripheral arterial disease, modifiable risk factors, and appropriate use of drugs in the treatment of peripheral arterial disease in older persons seen in a university general medicine clinic. J Gerontol A Biol Sci Med Sci (2005) 0.91

Effects of peripheral arterial disease on outcomes in advanced chronic systolic heart failure: a propensity-matched study. Circ Heart Fail (2009) 0.90